The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
New office in NL to strengthen networked R&D
Grünenthal’s IMU opens European center for Open Innovation in Leiden/NL, to enable easier access and close collaboration with leading scientists and institutions.
Grünenthal announced the opening of an Innovation Hub as an expansion of its Innovative Medicines Unit (IMU). The Hub will be located in Leiden, NL, and be embedded in the Leiden Bio Science Park, the largest cluster of biotech and pharmaceutical companies in the Netherlands and one of the five most successful science parks in Europe. The IMU – Leiden Hub will enable Grünenthal to engage even more strongly in networked R&D by building strong alliances and partnerships with academia, the biotech community and innovative service providers to jointly find solutions for patients suffering from illnesses with high unmet medical need and to bring these solutions faster to the patients.